Skip to main content
. Author manuscript; available in PMC: 2019 Jan 2.
Published in final edited form as: Clin Lung Cancer. 2014 Jan 1;15(3):202–206. doi: 10.1016/j.cllc.2013.12.009

Table 2:

Molecular Alterations Present in Tumor of Patients with LM. a. Suspected EGFR activating mutations defined as a patient who had a documented response to gefitinib or erlotinib on imaging in the absence of EGFR mutation testing.

Molecular Alteration Percent (number/total)
- K-ras mutation 7% (2/30)
- Known or Suspected EGFR activating mutationa 43% (13/30)
- ALK translocation 7% (2/30)
- EGFR Exon 20 insertion/PI3K mutation 3% (1/30)
- None/Unknown 40% (12/30)